Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.

BACKGROUND & AIMS Annual testing for fecal occult blood is recommended as first-line screening for the detection of colorectal cancer (CRC), but is affected by limited sensitivity. We initiated a proteomics-based search for novel biomarkers to improve the sensitivity of detection of CRC in stool samples. METHODS Six markers, including immunologic fecal occult blood test (iFOBT), were evaluated in a collective of 551 samples (186 CRC, 113 advanced adenoma, and 252 control patients) to establish the diagnostic performance of each marker and marker combinations. RESULTS We tested the known stool markers hemoglobin (iFOBT), hemoglobin-haptoglobin, calprotectin, carcinoembryogenic antigen, and the novel fecal markers tissue inhibitor of metalloproteinase-1 (TIMP-1) and S100A12. The best diagnostic performance was found for S100A12 with an area under the curve of 0.95, followed by TIMP-1 (0.92), hemoglobin-haptoglobin (0.92), hemoglobin (0.91), calprotectin (0.90), and carcinoembryogenic antigen (0.66). By using Bayes logistic regression as a mathematic model, the highest sensitivity (88%) for the detection of CRC at 95% specificity was obtained with the marker pair S100A12 and hemoglobin-haptoglobin. Increasing the specificity to 98%, the combination of S100A12, hemoglobin-haptoglobin, and TIMP-1 resulted in a sensitivity of 82%, with the highest increase of sensitivity found in early tumor stages (international union against cancer stage I: 74% sensitivity vs 57% of the best single marker). CONCLUSIONS Depending on the specificity selected, a marker pair, S100A12 and hemoglobin-haptoglobin, or a triple combination including TIMP-1, allowed the detection of CRC at significantly higher rates than can be obtained with iFOBT alone.

[1]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[2]  H. Nielsen,et al.  Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Ruth Etzioni,et al.  Early detection: The case for early detection , 2003, Nature Reviews Cancer.

[4]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[5]  H. Friess,et al.  Towards a comprehensive proteome of normal and malignant human colon tissue by 2‐D‐LC‐ESI‐MS and 2‐DE proteomics and identification of S100A12 as potential cancer biomarker , 2008, Proteomics. Clinical applications.

[6]  I. Bjarnason,et al.  Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma , 2001, Gut.

[7]  J. Olsen,et al.  Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.

[8]  C. Heizmann,et al.  Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. , 2003, Biochemical and biophysical research communications.

[9]  P. Maisonneuve,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.

[10]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[11]  D. Foell,et al.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome , 2007, Gut.

[12]  H. Schjønsby,et al.  Improved assay for fecal calprotectin. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[13]  L. Guittet,et al.  Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population , 2006, Gut.

[14]  David Madigan,et al.  Large-Scale Bayesian Logistic Regression for Text Categorization , 2007, Technometrics.

[15]  A. Day,et al.  Fecal S100A12: A novel noninvasive marker in children with Crohn's disease , 2006, Inflammatory bowel diseases.

[16]  O Fitzgerald,et al.  Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. , 2003, Rheumatology.

[17]  T. Morikawa,et al.  A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonoscopy in the Asymptomatic Population , 2005 .

[18]  A. Adrain,et al.  A comparison of fecal occult-blood tests for colorectal-cancer screening. , 1996, The New England journal of medicine.

[19]  Yonggoo Kim,et al.  Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. , 2003, Annals of clinical and laboratory science.

[20]  J. Barkin A Quantitative Immunochemical Fecal Occult Blood Test for Colorectal Neoplasia , 2008 .

[21]  D. Foell,et al.  Expression of S100A12 (EN-RAGE) in cystic fibrosis , 2003, Thorax.

[22]  A. Darzi,et al.  Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy , 2007, The American Journal of Gastroenterology.

[23]  Perry J Pickhardt,et al.  Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology * † , 2008, CA: a cancer journal for clinicians.

[24]  H. Nielsen,et al.  Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. , 2006, European journal of cancer.

[25]  S. Dudoit,et al.  Asymptotics of cross-validated risk estimation in estimator selection and performance assessment , 2005 .

[26]  L M Schuman,et al.  The effect of fecal occult-blood screening on the incidence of colorectal cancer. , 2000, The New England journal of medicine.

[27]  S. Markowitz,et al.  Improved fecal DNA test for colorectal cancer screening. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  D. Foell,et al.  S100A12 (EN-RAGE) in monitoring Kawasaki disease , 2003, The Lancet.

[29]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[30]  M. Vatn,et al.  Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT) , 2004, Gut.

[31]  A. Sieg,et al.  Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces , 1999, International Journal of Colorectal Disease.

[32]  D. Foell,et al.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease , 2003, Gut.

[33]  T. Morikawa,et al.  A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. , 2005, Gastroenterology.